RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 23 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Topotecan
Indications Small cell lung cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms RESILIENT
Sponsors Ipsen; Merrimack Pharmaceuticals

Most Recent Events

11 Aug 2023 This Trial has been completed in Hungary as per European Clinical Trials Database record.
08 Aug 2023 Status changed from active, no longer recruiting to completed.
13 Jul 2023 Planned End Date changed from 28 Apr 2023 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight